Vicriviroc (** No approved brand names (investigational drug only) **)

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Vicriviroc (MK-7690) is an experimental drug currently being studied in clinical trials. It is being investigated as a potential treatment for advanced or metastatic colorectal cancer (CRC), specifically in patients whose tumors are microsatellite stable (MSS). MSS CRC is a type of CRC that does not respond well to standard immunotherapy treatments. This trial is exploring whether combining vicriviroc with pembrolizumab (an immunotherapy drug) can be effective and safe for these patients. The goal is to see if this combination can help control or shrink the cancer.

Mechanism of Action

Vicriviroc is a CCR5 antagonist. CCR5 is a protein found on the surface of certain immune cells. By blocking CCR5, vicriviroc may affect the movement of these immune cells and potentially influence the tumor microenvironment. The specific way it interacts with the immune system and affects cancer cells in the context of MSS CRC is being studied in clinical trials. It is being tested in combination with pembrolizumab, which works by helping the immune system recognize and attack cancer cells.

Side Effects

As an investigational drug The full range of side effects for vicriviroc is still being evaluated in ongoing clinical trials. Common side effects observed in trials for other conditions involving vicriviroc have included nausea Fatigue And headache. When used in combination with pembrolizumab Side effects from both drugs may occur. Pembrolizumab can cause immune-related side effects affecting various organs. Patients participating in the trial will be closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03631407 Phase 2
Archived
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
United States, Canada

Quick Info

Brand Name** No approved brand names (investigational drug only) **
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
787 trials
Leucovorin
Other Medications
648 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.